Showing 1 posts of 1 posts found.
Novartis Kisqali (ribociclib) plus fulvestrant demonstrated a statistically significant improvement in overall survival rates, with an almost 30% reduction in …
Santen joins inaugural Global Summit for Eye Health as partner
EHP Awards 2027 open for entries following outstanding inaugural year
NHS spends £240m storing patient records as digital reforms gather pace
NHS awards national diabetes education contract to Leicester programme
InnoScot highlights NHS Scotland’s progress towards net zero healthcare